STOCK TITAN

Profit jumps 53% as Sono-Tek (NASDAQ: SOTK) lifts Q1 margins

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Sono-Tek Corporation reported strong first quarter fiscal 2027 results with higher sales, margins, and profits. Net sales rose 10% to $5.66 million, driven mainly by medical markets. Gross margin expanded from 52% to 57%, lifting gross profit 21% to $3.21 million.

Operating income increased 86% to $897,000, while net income grew 53% to $741,000, or $0.05 per diluted share. Cash, cash equivalents, and marketable securities totaled $16.65 million with no debt, and backlog was $7.73 million. Management expects continued revenue growth and profitability in the first half of fiscal 2027, but only flat to modest revenue growth for the full year due to clean energy uncertainty and shipment timing for large systems.

Positive

  • Strong profitability and margin expansion: Revenue grew 10% to $5.66 million, while gross margin expanded to 57% and net income rose 53% to $741,000, demonstrating significant operating leverage from higher-value medical and production system sales.

Negative

  • None.

Insights

Quarter shows strong profit leverage from higher-margin medical systems.

Sono-Tek delivered 10% revenue growth to $5.66 million with outsized profit gains: operating income rose 86% to $897,000 and net income climbed 53% to $741,000. A richer mix of medical and higher-value production systems pushed gross margin to 57%.

The business mix is shifting sharply: medical market sales reached $3.95 million, about 70% of revenue, while Alternative Energy/Clean fell 90% year over year. This concentration in medical devices supports margins but increases dependence on one end market.

The balance sheet remains solid with $16.65 million in cash, cash equivalents, and marketable securities and no debt, providing flexibility to keep investing in engineering and commercial capabilities. Management projects continued growth and profitability in the first half of fiscal 2027, yet only flat to modest revenue growth for the full year as clean energy demand and large-system shipment timing remain uncertain.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Net sales $5.66 million Three months ended May 31, 2026, up 10% year over year
Gross margin 57% Three months ended May 31, 2026, vs 52% prior-year period
Net income $741,000 Three months ended May 31, 2026, up 53% year over year
Diluted EPS $0.05 per share Three months ended May 31, 2026, vs $0.03 prior-year period
Cash and marketable securities $16.65 million Cash, cash equivalents, and marketable securities with no debt
Backlog $7.73 million Backlog at May 31, 2026; up 3% vs May 31, 2025
Medical market sales $3.95 million Three months ended May 31, 2026, about 70% of total sales
Alternative Energy/Clean sales $319,000 Three months ended May 31, 2026, down from $3.25 million
gross margin financial
"Gross margin expanded to 57% from 52%"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
backlog financial
"Combined equipment and service-related backlog at May 31, 2026 was $7.73 million"
A backlog is the amount of work or orders that a company has received but hasn't completed yet. It’s like a restaurant with many dishes to serve; the backlog shows how many orders are still waiting to be finished. It matters because a large backlog can indicate strong demand or potential delays in delivering products or services.
Alternative Energy/Clean financial
"Alternative Energy/Clean: $319,000 vs. $3.25 million"
Drug-Eluting Balloon platforms technical
"Drug-Eluting Balloon platforms across the U.S., China, and Europe"
ultrasonic coating systems technical
"a leading developer and manufacturer of precision ultrasonic coating systems"
Ultrasonic coating systems are manufacturing machines that use high‑frequency vibrations to turn liquids into extremely fine droplets, then lay them down as thin, even films on products like electronics, medical devices, or packaging. For investors, they matter because the technology can improve product performance and yield while cutting material waste and production costs—think of painting with a fine, precise spraygun instead of a messy brush—so companies using it may gain quality or efficiency advantages.
forward looking statements regulatory
"This news release contains forward looking statements regarding future events"
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
Net sales $5.66 million +10% year over year
Gross margin 57% up from 52% prior-year period
Net income $741,000 +53% year over year
Diluted EPS $0.05 vs $0.03 prior-year period
Guidance

Company projects continued revenue growth and profitability in the first half of fiscal 2027 and flat to modest full-year revenue growth versus fiscal 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How did Sono-Tek (SOTK) perform in Q1 fiscal 2027?

Sono-Tek delivered strong Q1 fiscal 2027 results with net sales up 10% to $5.66 million. Gross margin improved to 57%, operating income rose 86% to $897,000, and net income increased 53% to $741,000, or $0.05 per diluted share.

What drove Sono-Tek’s revenue growth in the latest quarter?

Revenue growth was primarily driven by medical market demand, which reached $3.95 million and about 70% of total sales. Strong orders for specialty stent coating systems and Drug-Eluting Balloon platforms, plus higher-value production platforms, more than offset weaker Alternative Energy/Clean shipments.

How strong is Sono-Tek’s balance sheet after Q1 fiscal 2027?

Sono-Tek ended the quarter with a solid balance sheet, holding $16.65 million in cash, cash equivalents, and marketable securities and no debt. Total stockholders’ equity was $20.61 million, giving the company financial flexibility to fund growth initiatives and navigate demand variability.

What is Sono-Tek’s backlog and what does it indicate?

Backlog at May 31, 2026 was $7.73 million, up $250,000 or 3% from May 31, 2025, but down from $9.12 million at fiscal 2026 year-end. This suggests continued underlying demand, though timing of large production platform shipments affects near-term visibility.

What outlook did Sono-Tek provide for fiscal 2027 revenues?

Management expects continued revenue growth and profitability in the first half of fiscal 2027 versus the prior-year first half. For the full fiscal year, total revenue is projected to be relatively flat to modestly higher than fiscal 2026, reflecting clean energy uncertainty and shipment timing for large systems.

How did Sono-Tek’s market mix change in the quarter?

The market mix shifted toward medical, which rose to $3.95 million versus $809,000 a year earlier. Alternative Energy/Clean fell to $319,000 from $3.25 million, while Industrial and Latin America sales grew strongly, underscoring diversification beyond clean energy applications.
false 0000806172 SONO TEK CORP 0000806172 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 8, 2026

 

Sono-Tek Corporation

(Exact name of registrant as specified in its charter)

 

Commission File Number: 001-40763

 

New York   14-1568099
(State of Incorporation)   (I.R.S. Employer ID No.)
     
2012 Route 9W, Milton, New York   12547
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (845) 795-2020

 

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share SOTK NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Item 2.02: Results of Operations and Financial Condition.

Item 7.01: Regulation FD Disclosure

 

On July 8, 2026, Sono-Tek Corporation issued a press release regarding its financial results for the quarter ended May 31, 2026 in the form attached as exhibit 99.1.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under such section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01: Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1       Press Release dated July 8, 2026.

104        Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SONO-TEK CORPORATION

 

By: /s/ Stephen J. Bagley

Stephen J. Bagley

Chief Financial Officer

July 8, 2026

 

Exhibit 99.1

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

Revenue Increased 10%; Gross Margin Expanded to 57%; Operating Income Increased 86%; Net Income Increased 67%

Anticipating Continued Revenue Growth in 1H 2027 Driven by Strong Medical Sector and Higher Value Production Systems

MILTON, N.Y., July 8, 2026 – Sono-Tek Corporation (Nasdaq: SOTK), a leading developer and manufacturer of precision ultrasonic coating systems, today reported financial results for the first quarter of fiscal 2027, ended May 31, 2026.

First Quarter Fiscal 2027 Highlights

  • Net sales increased 10% to $5.66 million
  • Gross margin expanded to 57% from 52%
  • Gross profit increased 21% to $3.21 million
  • Operating income increased 86% to $897,000
  • Net income increased 53% to $741,000, or $0.05 per diluted share
  • Cash, cash equivalents, and marketable securities increased to $16.65 million with no debt
  • Backlog increased to approximately $7.73 million

Steve Harshbarger, CEO & President of Sono-Tek, stated:

"Fiscal 2027 is off to a strong start with double-digit revenue growth, meaningful margin expansion, and improved profitability, reflecting disciplined execution across our operations and the continued success of our strategy of focusing on higher-value production systems in advanced technology markets, particularly medical devices.

"Our medical business was the primary growth driver this quarter, with strong demand for specialty stent coating systems and Drug-Eluting Balloon platforms across the U.S., Europe, and Asia. This exceptional mix of business-including a higher concentration of medical systems, shipments of higher-value production platforms, and a greater proportion of U.S. based sales with lower distributor commission expenses, was a significant contributor to our gross margin expansion. While we are very pleased with these results, product mix, geographic mix, and shipment timing naturally fluctuate from quarter to quarter, and we would not expect this level of gross margin to be representative of every future quarter. Our technology is increasingly being selected for applications requiring highly controlled, repeatable thin-film coatings, positioning Sono-Tek to benefit as manufacturing precision requirements continue to increase across multiple industries.

 

"Looking ahead, we remain focused on expanding our installed base of production systems, supporting customers as they scale from development into commercial manufacturing, and investing in the engineering and commercial capabilities that will drive our next phase of growth. The Company continues to project revenue growth during the first half of fiscal 2027, supported by strong medical demand and continued shipments of higher-value production systems, and we maintain our previously communicated expectation of flat to modest revenue growth for the full fiscal year. This full-year outlook primarily reflects the timing of several large production platform orders. As these higher-value production systems become a larger portion of our business, quarterly revenue may increasingly be influenced by shipment timing. Our strong balance sheet provides the flexibility to execute these priorities while continuing to create long-term value for shareholders."

Dr. Christopher L. Coccio, Executive Chairman, added:

"Our first quarter results reinforce the long-term strength of Sono-Tek's ultrasonic coating technology platform and validate the strategic direction that we have pursued for many years. As precision manufacturing requirements continue to increase across advanced industries, we believe we are well positioned to expand our leadership through continued innovation and differentiated application expertise.

"We have spent decades building differentiated technology, deep application expertise, and lasting customer relationships that continue to position us for future success. We believe these enduring strengths, together with disciplined investment and a strong financial foundation, position Sono-Tek to capitalize on attractive long-term growth opportunities while creating lasting shareholder value."

First Quarter Fiscal 2027 Results

Net sales increased 10% to $5.66 million, driven by strong Medical demand, partially offset by lower Alternative Energy shipments compared with the prior-year period.

Gross profit increased 21% to $3.21 million, with gross margin expanding from 52% to 57% due to favorable product mix and higher-value system shipments.

Operating expenses increased 6% to $2.32 million due to continued investment in sales, engineering, and business development initiatives.

Operating income increased 86% to $897,000.

Net income increased 53% to $741,000, or $0.05 per diluted share.

 

 

First Quarter Fiscal 2027 Results – (compared with the prior year period)

   Three Months Ended May 31,   Change 
   2026   2025   $   % 
Net Sales  $5,661,000   $5,133,000    528,000    10% 
Gross Profit   3,214,000    2,665,000    549,000    21% 
          Gross Margin   57%    52%           
Operating Income  $897,000   $483,000    414,000    86% 
          Operating Margin   16%    9%           
Net Income  $741,000   $485,000    256,000    53% 
          Net Margin   13%    9%           
Basic Earnings Per Share  $0.05   $0.03           
Diluted Earnings Per Share  $0.05   $0.03           
Weighted Average Shares -Basic   15,713,000    15,734,000           
Weighted Average Shares - Diluted   15,737,000    15,749,000           

 

First Quarter Fiscal 2027 Product and Market Highlights

Market Sales

  • Medical: $3.95 million vs. $809,000
  • Electronics/Microelectronics: $863,000 vs. $943,000
  • Alternative Energy/Clean: $319,000 vs. $3.25 million
  • Industrial: $530,000 vs. $119,000
  • Emerging R&D and Other: $3,000 vs. $14,000

Medical growth was driven by specialty stent coating systems in the U.S. and Drug-Eluting Balloon platforms across the U.S., China, and Europe. Alternative Energy declined due to reduced electrolysis demand and the absence of solar shipments. Industrial growth reflected system upgrades and R&D nano-coating applications.

Product Sales

  • Fluxing Systems: $92,000 vs. $152,000
  • In-Line Coating Systems: $2.16 million vs. $3.05 million
  • Multi-Axis Coating Systems: $2.08 million vs. $677,000
  • OEM Systems: $231,000 vs. $130,000
  • Spare Parts, Services and Other: $1.10 million vs. $1.12 million
  • Total Net Sales: $5.66 million vs. $5.13 million

 

Multi-Axis growth was driven by strong demand across multiple end markets. In-Line declined due to reduced clean energy shipments, including the absence of prior-year solar system deliveries. OEM Systems increased on semiconductor and fluxer OEM demand, while services remained stable.

Balance Sheet, Backlog and Outlook

Balance Sheet: Cash, cash equivalents, and marketable securities totaled $16.65 million, compared with $14.81 million at the prior year end. The Company had no outstanding debt.

Backlog: Combined equipment and service-related backlog at May 31, 2026 was $7.73 million, compared to backlog of $7.48 million at May 31, 2025, an increase of $250,000, or 3%. Backlog was down $1.39 million compared to the fiscal 2026 year-end level of $9.12 million.


Outlook: Sono-Tek anticipates continued revenue growth and profitability in the first half of fiscal year 2027 compared to the first half of fiscal year 2026, driven by expanding demand in the medical sector and continued adoption of high value production-scale coating systems across multiple end markets. Total fiscal year 2027 revenue is currently projected to be relatively flat to modestly higher compared to fiscal year 2026, as visibility beyond the first half remains limited due to continued uncertainty in certain clean energy sectors and the timing of shipments for higher value production scale platforms.

 

About Sono-Tek

 

Sono-Tek Corporation is a global leader in the design and manufacture of ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts used in diverse industries including microelectronics, alternative energy, medical devices, advanced industrial manufacturing, and research and development sectors worldwide. Sono-Tek's inroads into the clean energy sector have shown transformative results in next-gen solar cells, fuel cells, green hydrogen generation, and carbon capture applications.

 

Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability. Our comprehensive suite of thin film coating solutions and application consulting services are expected to generate unparalleled results for our clients and help some of the world's most promising companies achieve technological breakthroughs and bring them to the market. We strategically deliver our products to customers through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives, ensuring efficient market reach across diverse sectors around the globe.

 

Our solutions are environmentally friendly, efficient and highly reliable, and enable dramatic reductions in overspray, savings in raw material, water and energy usage and provide improved process repeatability, transfer efficiency, high uniformity and reduced emissions.

 

 

Our growth strategy is focused on leveraging our innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop thin film coating technologies that enable better outcomes for our customers’ products and processes. For further information, visit www.sono-tek.com

 

Safe Harbor Statement

 

This news release contains forward looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These “forward-looking statements’ are based on currently available competitive, financial and economic data and our operating plans. They are inherently uncertain, and investors must recognize that events could turn out to be significantly different from our expectations and could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions, including political, regulatory, tax, competitive and technological developments affecting our operations or the demand for our products; inflationary and supply chain pressures; continued strength of sales to the medical device and electronics markets; increased private and public funding for the clean energy sector; continued strong demand for Sono-Tek’s suite of thin film coating solutions and application consulting services in the clean energy and other markets; maintenance of order backlog; evolving tariff policies; timely development and market acceptance of new products and continued customer validation of our coating technologies; adequacy of financing; capacity additions, the ability to enforce patents; maintenance of operating leverage; consummation of order proposals; timing of large orders and completion on schedule and on budget; successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems; and realization of first half and annual revenues and profitability within the forecasted ranges of guidance. We undertake no obligation to update any forward-looking statement.

 

For more information:

 

Sono-Tek Corp.

Stephen J. Bagley

Chief Financial Officer

Ph: (845) 795-2020

info@sono-tek.com

 

Investor Relations

Kirin Smith, President

PCG Advisory, Inc.

ksmith@pcgadvisory.com

- Financial Tables to follow –

 

SONO-TEK CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   May 31, 2026   February 28, 
   (Unaudited)   2026 
ASSETS          
Current Assets:          
Cash and cash equivalents  $8,982,075   $7,339,403 
Marketable securities   7,669,872    7,469,649 
Accounts receivable (less allowance of $12,225, respectively)   1,264,932    3,350,953 
Inventories   4,063,132    3,923,350 
Prepaid expenses and other current assets   659,518    743,295 
Total current assets   22,639,529    22,826,650 
           
Land   250,000    250,000 
Buildings, equipment, furnishings and leasehold improvements, net   2,138,226    2,173,443 
Intangible assets, net   27,892    29,791 
Deferred tax asset   809,182    1,141,611 
           
TOTAL ASSETS  $25,864,829   $26,421,495 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current Liabilities:          
Accounts payable  $935,442   $1,038,885 
Accrued expenses   2,088,229    2,227,401 
Customer deposits   2,006,896    3,069,743 
Income taxes payable   147,984    255,398 
Total current liabilities   5,178,551    6,591,427 
           
Deferred tax liability   75,238    55,909 
Total liabilities   5,253,789    6,647,336 
           
Commitments and Contingencies (Note 10)        
           
Stockholders’ Equity          
Common stock, $.01 par value; 25,000,000 shares authorized, 15,716,723 and 15,710,389 issued and outstanding as of May 31, 2026 and February 28, 2026   157,167    157,104 
Additional paid-in capital   10,282,508    10,186,858 
Accumulated earnings   10,171,365    9,430,197 
Total stockholders’ equity   20,611,040    19,774,159 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $25,864,829   $26,421,495 

 

See notes to unaudited condensed consolidated financial statements.

 

 

SONO-TEK CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

 

   Three Months Ended May 31, 
   2026   2025 
         
Net Sales  $5,661,159   $5,132,773 
Cost of Goods Sold   2,447,241    2,468,259 
Gross Profit   3,213,918    2,664,514 
           
Operating Expenses          
Research and product development costs   616,982    668,470 
Marketing and selling expenses   1,024,984    858,151 
General and administrative costs   674,792    654,525 
Total Operating Expenses   2,316,758    2,181,146 
           
Operating Income   897,160    483,368 
           
Interest and Dividend Income   114,624    142,098 
Net unrealized (loss) on marketable securities   (26,271)   (21,923)
           
Income Before Income Taxes   985,513    603,543 
           
Income Tax Expense   244,345    118,558 
           
Net Income  $741,168   $484,985 
           
Basic Earnings Per Share  $0.05   $0.03 
           
Diluted Earnings Per Share  $0.05   $0.03 
           
Weighted Average Shares - Basic   15,713,185    15,733,955 
           
Weighted Average Shares - Diluted   15,737,276    15,748,556 

 

See notes to unaudited condensed consolidated financial statements.

 

 

SONO-TEK CORPORATION

PRODUCT, MARKET, AND GEOGRAPHIC SALES

(Unaudited)

 

Product Sales:

    Three Months Ended May 31,   Change
    2026     % of total   2025     % of total   $     %
Fluxing Systems   $ 92,000     2%   $ 152,000     3%     (60,000 )   (39%)
In-Line Coating Systems     2,159,000     38%     3,054,000     59%     (895,000 )   (29%)
Multi-Axis Coating Systems     2,075,000     37%     677,000     13%     1,398,000     206%
OEM Systems     231,000     4%     130,000     3%     101,000     78%
Spare Parts, Services and Other     1,104,000     20%     1,120,000     22%     (16,000 )   1%
TOTAL   $ 5,661,000         $ 5,133,000         $ 528,000     10%

 

Market Sales: 

    Three Months Ended May 31,   Change
    2026     % of total   2025     % of total   $     %
Electronics/Microelectronics   $ 863,000     15%   $ 943,000     19%     (80,000   (8%)
Medical     3,946,000     70%     809,000     16%     3,137,000     388%
Alternative Energy/Clean     319,000     6%     3,248,000     63%     (2,929,000   (90%)
Emerging R&D and Other     3,000     0%     14,000     0%     (11,000 )   (79%)
Industrial     530,000     9%     119,000     2%     411,000     345%
TOTAL   $ 5,661,000         $ 5,133,000         $ 528,000     10%

 

Geographic Sales:

    Three Months Ended              
    May 31,     Change  
    2026     2025     $     %  
U.S. & Canada   $ 3,530,000     $ 3,543,000     $ (13,000   0%  
Asia Pacific (APAC)     738,000       597,000       141,000     24%  
Europe, Middle East, Africa (EMEA)     930,000       897,000       33,000     4%  
Latin America     463,000       96,000       367,000     382%  
TOTAL   $ 5,661,000     $ 5,133,000     $ 528,000     10%  

 

 

 

Filing Exhibits & Attachments

4 documents